GENOME THERAPEUTICS CORP Form 4 March 14, 2003 SEC Form 4

FORM 4	UNIT	ED STATES SECURI COMMIS	θE	OMB APPROVAL			
[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	Filed pursua	Washington, I EMENT OF CHANGES IN ant to Section 16(a) of the Sec 17(a) of the Pu apany Act of 1935 or Section 3 1940	Section				
1. Name and Address of Repor Rauscher, Steven M (Last) (First) (Middle) 100 Beaver Street Waltham, MA (Street) (City) (State) (Zip)	ting Person*	 2. Issuer Name and Ticker or Trading Symbol Genome Therapeutics Corp. GENE 3. I.R.S. Identification Number of Reporting Person, if an entity (voluntary) 	 4. Statement for (Month/Day/Year 03/12/2003 5. If Amendment, Date of Original (Month/Day/Year) 	to Issue _ Direc: X Office (specify Preside 7. Indiv Filing X Forr Person	(Check all applicable) Director _ 10% Owner Officer (give title below) _ Other Decify below) escription <u>CEO and</u> esident Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting rson Form filed by More than One		

	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									
1. Title of Security (Instr. 3)	2.Transaction Date (Month/Day/Year)	e Execution Date, if Trans nth/Day/Year) (Month/Day/Year) Co (Instance) (Instance)	Transaction Code (Instr.		4. Securities Acquired h(A) or Disposed Of (D) (Instr. 3, 4, and 5)			5. Amount of Securities Beneficially Owned Following (D) 6. Owner- ship Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
			Code	V	Amount	A/D	Price	Reported or Transaction(s) Indirect (I) (Instr. 3 and 4) (Instr. 4)	(Instr. 4)	

				Table II		curities Acquired, Dispose Is, warrants, options, con	•)wned	
1. Title of Derivative Security (Instr. 3)	2. Conver- sion or Exercise Price of Deri- vative Security	3. Transaction Date (Month/ Day/ Year)	3A. Deemed Execution Date, if any (Month/ Day/ Year)	4. Transactio Code (Instr.8)	5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)	6. Date Exercisable(DE) and Expiration Date(ED) (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr.5)	9. Num Deri Sect Ben Owr Follo Rep Trar (Inst

Edgar Filing: GENOME THERAPEUTICS CORP - Form 4

			Code	V	A	D	DE	ED	Title	Amount or Number of Shares		
Stock Option (right to buy)	\$.384	03/12/2003	A		33,002		03/12/2003	03/12/2013	Common Shares	33,002	N/A	
Stock Option (right to buy)	\$.384	03/12/2003	A		33,002		03/12/2004	03/12/2013	Common Shares	33,002	N/A	74

Explanation of Responses:

By:	Date:
<u>/s/ Steven M. Rauscher</u>	<u>03/14/03</u>
** Signature of Reporting Person	SEC 1474 (9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not

required to respond unless the form displays a currently valid OMB Number.